“I am too conflicted to take on this challenge. People without conflicts of interests will need to take the fight to the DoH and Government”, concludes ProfG.
Rachel Horne interviews ProfG to ascertain why the Department of Health and NICE have said no to ocrelizumab for treating people with PPMS.
“We don’t care a toss about PPMSers, all we are worried about is rationing high-cost drugs and making sure we keep the system simple”, said a DoH spokesperson. “We cannot change the NHS accounting system to have two prices for the same drug”, he added
“Why?”, asked Prof G.
“Don’t you understand, how the NHS works?”, he replied.